← Leaderboards
Paul A. Goepfert
University Of Alabama At Birmingham
$51,350,070
Attributed
$64,025,106
Total exposure
20
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$65,058,390 · 21
By mechanism
R01$28,462,935 · 7
P30$22,787,773 · 6
UM1$7,156,630 · 1
U01$3,526,676 · 1
R56$1,298,350 · 2
U19$1,033,284 · 1
Top collaborators
- Eric Hunter11 shared
- Jianming Tang7 shared
- Anju Bansal6 shared
- Richard A Kaslow4 shared
- Nilam Sanjib Banerjee2 shared
- Nathaniel Bernard Erdmann1 shared
- W Timothy Garvey1 shared
- James O Hill1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Eric Hunter$78,178,241
- Richard A Kaslow$6,549,974
- Sarah L Morgan$971,091
- Jianming Tang$7,968,768
- Jeffrey R. Curtis$9,424,518
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignBaseHiv InfectionsResponsePreventionHiv-1InfectionViralSamplingFutureImmuneVirusEpidemicVaccinesResearch PersonnelImmune ResponseEpitopesCollaborationsChronicCohortAcquired Immunodeficiency SyndromeGrantVaccine DesignLink
Grant awards (72)
A-Z Clinical Trials Unit$1,734,507
UM1 · FY2025 · AI · contact PI
Onco-immunologic factors contributing to OPSCC among people living with HIV$697,916
R01 · FY2025 · DE
Developmental Core (Core B)$258,071
P30 · FY2025 · AI · contact PI
A-Z Clinical Trials Unit$1,659,641
UM1 · FY2024 · AI · contact PI
Onco-immunologic factors contributing to OPSCC among people living with HIV$672,147
R01 · FY2024 · DE
Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responses$614,212
R01 · FY2024 · AI · contact PI
Developmental Core (Core B)$392,387
P30 · FY2024 · AI · contact PI
Developmental Core (Core B)$329,189
P30 · FY2024 · AI · contact PI
Developmental Core (Core B)$159,777
P30 · FY2024 · AI · contact PI
A-Z Clinical Trials Unit$1,862,682
UM1 · FY2023 · AI · contact PI
Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responses$630,755
R01 · FY2023 · AI · contact PI
Core B Developmental Core$563,014
P30 · FY2023 · AI · contact PI
Core B Developmental Core$519,750
P30 · FY2023 · AI · contact PI
Core B Developmental Core$222,750
P30 · FY2023 · AI · contact PI
Core B Developmental Core$222,750
P30 · FY2023 · AI · contact PI
A-Z Clinical Trials Unit$1,899,800
UM1 · FY2022 · AI · contact PI
Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responses$1,050,409
R01 · FY2022 · AI · contact PI
Tissue and organ specific human B cell immunity: Supplement - Metabolic Risk Factors and Inflammation in PASC Development$1,033,284
U19 · FY2022 · AI
Core B Developmental Core$750,791
P30 · FY2022 · AI · contact PI
Core B Developmental Core$1,362,131
P30 · FY2021 · AI · contact PI
Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responses$656,616
R01 · FY2021 · AI · contact PI
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses$628,066
R01 · FY2021 · AI · contact PI
Core B Developmental Core$1,461,384
P30 · FY2020 · AI · contact PI
The impact of HIV adaptation to CD8 T cells on infection and viral control$662,144
R56 · FY2020 · AI · contact PI
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses$636,864
R01 · FY2020 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,615,187
R01 · FY2019 · AI
Core B Developmental Core$1,223,290
P30 · FY2019 · AI · contact PI
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses$679,465
R01 · FY2019 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,605,525
R01 · FY2018 · AI
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses$718,896
R01 · FY2018 · AI · contact PI
Developmental Core$255,870
P30 · FY2018 · AI · contact PI
Developmental Core$2,508,540
P30 · FY2017 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,627,401
R01 · FY2017 · AI
Defining the biological relevance of HIV-1 adaptation to CD4 T cell responses$790,033
R01 · FY2017 · AI · contact PI
A Rational Approach for HIV Vaccine T Cell Epitope Selection$463,752
R01 · FY2017 · AI · contact PI
Developmental Core$3,237,572
P30 · FY2016 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,627,401
R01 · FY2016 · AI
A Rational Approach for HIV Vaccine T Cell Epitope Selection$463,752
R01 · FY2016 · AI · contact PI
Developmental Core$3,262,258
P30 · FY2015 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,534,304
R01 · FY2015 · AI
A Rational Approach for HIV Vaccine T Cell Epitope Selection$462,568
R01 · FY2015 · AI · contact PI
Developmental Core$3,588,081
P30 · FY2014 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,426,271
R01 · FY2014 · AI
A Rational Approach for HIV Vaccine T Cell Epitope Selection$487,685
R01 · FY2014 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,340,695
R01 · FY2013 · AI
HIV-1 Cryptic Epitopes: Implications for Vaccine Design$451,070
R01 · FY2013 · AI · contact PI
DNA Sequencing$74,283
P30 · FY2013 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,426,271
R01 · FY2012 · AI
Analysis of Variant Epitope Specific CD8 T-Cells to Optimize HIV Vaccine Design$636,206
R56 · FY2012 · AI · contact PI
DNA Sequencing$522,966
P30 · FY2012 · AI · contact PI
HIV-1 Cryptic Epitopes: Implications for Vaccine Design$500,421
R01 · FY2012 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,437,996
R01 · FY2011 · AI
Clinical$694,806
P30 · FY2011 · AI · contact PI
HIV-1 Cryptic Epitopes: Implications for Vaccine Design$501,903
R01 · FY2011 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$1,536,864
R01 · FY2010 · AI
Clinical$636,982
P30 · FY2010 · AI · contact PI
HIV-1 Cryptic Epitopes: Implications for Vaccine Design$517,068
R01 · FY2010 · AI · contact PI
CTL and HIV Polymorphisms in Heterosexual Transmission$250,582
R01 · FY2010 · AI
HIV-1 Cryptic Epitopes: Implications for Vaccine Design$522,788
R01 · FY2009 · AI · contact PI
Clinical$386,612
P30 · FY2009 · AI · contact PI
HIV-1 Suppression by MHC class I restricted CD8 T Cells$177,806
R21 · FY2008 · AI · contact PI
Clinical$154,519
P30 · FY2008 · AI · contact PI
HIV-1 Suppression by MHC class I restricted CD8 T Cells$217,500
R21 · FY2007 · AI · contact PI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)$709,372
U01 · FY2006 · AI · contact PI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)$1,517,556
U01 · FY2005 · AI
CD8+ T Cell Cytokine Production in HIV-1 Infection$253,750
R01 · FY2005 · AI
ALABAMA/ZAMBIA HIV VACCINE CLINICAL TRIALS UNIT (HVTU)$1,299,748
U01 · FY2004 · AI
CD8+ T Cell Cytokine Production in HIV-1 Infection$253,750
R01 · FY2004 · AI
CD8+ T Cell Cytokine Production in HIV-1 Infection$253,750
R01 · FY2003 · AI
CD8+ T Cell Cytokine Production in HIV-1 Infection$126,802
R01 · FY2002 · AI
CD8+ T cell cytokine production in HIV-1 infection$276,125
R21 · FY2001 · AI
HUMAN FOAMY VIRUS STRUCTURAL PROTEINS$121,311
K08 · FY2000 · AI